Lantheus Holdings stock in focus after third-quarter results

Published on 11/12/2026 at 03:31 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Lantheus Holdings stock remains in focus after the company released its third-quarter results. Its radiopharmaceutical portfolio spans oncology and precision diagnostics.

Lantheus results remain in focus

Lantheus published its third-quarter 2026 results on November 5.
The company continues to focus on radiopharmaceutical oncology, precision diagnostics and strategic partnerships.

LNTH, US5165441032, Illustration mit AI erstellt.

Lantheus Holdings stock traded at 91.10 euros on Lang & Schwarz at 23:00 CET on Wednesday, November 11, 2026. The company remains in focus after publishing its third-quarter 2026 results on November 5, while investors continue to assess the outlook for its radiopharmaceutical business.

Third-quarter results set the backdrop

Lantheus listed its third-quarter financial results among its latest releases on November 5. The release came alongside an update on the company's product and market priorities, keeping operating performance and the pending strategic transaction central to the investment case.

The company has suspended its previously issued full-year 2026 guidance in connection with the proposed merger with Curium, according to the company's third-quarter results announcement summarized in the release materials. The transaction therefore remains an important consideration for shareholders alongside the underlying business performance.

Radiopharmaceutical platform spans markets

Lantheus develops radiopharmaceutical products for oncology, precision diagnostic products with a focus on cardiology, and solutions built around biomarkers, digital tools and pharmaceutical platforms. Its products are used by nuclear medicine physicians, oncologists, radiologists, urologists, cardiologists and other clinical professionals across the United States and international markets.

The company's investor-relations site lists Massachusetts as its headquarters and offices in New Jersey, Canada, Germany, Sweden, Switzerland and the United Kingdom. Lantheus presents its portfolio through three categories: Radiopharmaceutical Oncology, Precision Diagnostics and Strategic Partnerships.